Table 1.
Entry | Company | Year drug discovery initiated | Year company established | Rank[a] | Estimated drug discovery or R&D headcount (year) | Total pipeline compounds[b] | Status 2016 |
---|---|---|---|---|---|---|---|
1 | Dr. Reddy's Laboratories | 1994 | 1984 | 2 | 320 in NCE R&D (2005) | 27 | Exited drug discovery in 2009 |
2 | Ranbaxy (now part of Sun Pharma) | 1995 | 1961 | (−)[c] | 280 in “New Drug Discovery Research”; 1400 in R&D (2008) | 16 | Exited drug discovery in 2008 after acquisition by Daiichi‐Sankyo |
3 | Torrent Pharmaceuticals | 1997 | 1972 | 9 | 130 in NCE discovery research (2008–14) | 6 | Active NCE R&D, three compounds in pipeline |
4 | Wockhardt Ltd. | 1997 | 1967 | 13 | 850 in R&D (2015) | 15 | Active NCE R&D, five compounds in pipeline |
5 | Piramal Life Sciences | 1998 | 1988 | 17 | 360 in NCE R&D (2011) | 16 | Exited drug discovery in 2014 |
6 | Dabur Research Foundation (now Fresenius‐Kabi Oncology) | 1998 | 1886 | (−)[d] | 20 in oncology drug discovery (2001) | 0 | Exited drug discovery in 2010 after acquisition by Fresenius‐Kabi |
7 | Sun Pharma | 1999 | 1993 | 1 | 275 at SPARC R&D (2015) | 8 | Active NCE R&D, three compounds in pipeline |
8 | Alembic Ltd. | 1999 | 1907 | 20 | NA | 0 | Collaboration with NCL (1999‐2003); investment in Incozen Therapeutics and Rhizen Pharmaceuticals (2008) |
9 | Zydus Cadila (Cadila Healthcare) | 2000 | 1995 | 6 | 250 in NCE R&D (2016) | 15 | Active NCE R&D, one compound launched (2013), four compounds in pipeline |
10 | Cadila Pharmaceuticals | 2000 | 1995 | 34 | NA | 0 | Develops mainly combination preparations; drug discovery collaboration with IIIM |
11 | FDC Ltd. | 2000 | 1940 | 42 | NA | 1 | Patent filings (2002–13) with National Chemical Laboratory (Pune), no internal drug discovery |
12 | JB Chemicals & Pharmaceuticals | 2000 | 1976 | 37 | NA | 1 | Exited drug discovery in 2006 |
13 | Cipla | 2000 | 1935 | 5 | NA | 0 | Patent filings (2000–01) with University of Mumbai, no internal drug discovery |
14 | Glenmark Pharmaceuticals | 2001 | 1977 | 8 | 300 NCE R&D (2015) | 19 | Active NCE R&D, four compounds licensed (all failed), one under option agreement (ongoing), one additionalcompound in pipeline |
15 | Lupin Ltd. | 2001 | 1972 | 3 | ∼130 in NCE drug discovery, 320 in R&D (2015) | 7 | Active NCE R&D, four compounds in pipeline |
16 | Reliance Life Sciences | 2001 | 2001 | 58 | NA | 2 | Exited NCE R&D in 2010 |
17 | Orchid Pharma | 2002 | 1992 | 47 | 130 in drug discovery (2013) | 5 | Halted drug discovery in 2014; one compound licensed to Allecra (2013), development ongoing |
18 | Suven Life Sciences | 2003 | 1989 | 59 | 120 in NCE R&D, out of 386 in R&D (2016) | 15 | Active NCE R&D, eleven compounds in pipeline |
19 | Natco Pharma | 2004 | 1981 | 38 | 15 in oncology drug discovery (2014) | 3 | Active NCE R&D, two compounds in pipeline |
20 | Panacea Biotech | 2005 | 1984 | 51 | 110 in drug discovery (2013) | 4 | Halted internal drug discovery in 2014; two compounds in pipeline |
21 | Matrix Laboratories (now Mylan) | 2005 | 2000 | (−)[e] | 18 in drug discovery (2006) | 2 | Exited drug discovery after acquisition by Mylan (2006) |
22 | Hetero Drugs | 2006 | 1993 | 7 | NA | 2 | NCE drug discovery mainly targeting HIV, also HCV, diabetes and cancer |
23 | Jubilant Life Sciences | 2007 | 1978 | 11 | NA | 3 | Active NCE R&D, three compounds in pipeline (one licensed in 2016) |
24 | Elder Pharmaceuticals | 2008 | 1989 | 44 | NA | 0 | Patents filed with Poona College of Pharmacy (2008), no internal drug discovery |
25 | IPCA Laboratories | 2009 | 1949 | 22 | NA | 0 | Claimed two compounds in pipeline (2012), but no development reported |
26 | Mankind Pharma | 2011 | 1995 | 15 | NA | 0 | No published NCE patent applications |
27 | Alkem Laboratories | 2013 | 1973 | 12 | 20 in drug discovery (2014) | 1 | Exited drug discovery prior to going public in 2015 |
28 | Emcure | 2014 | 1981 | 26 | NA | 0 | One published NCE patent application |
Total: 168 |
[a] Ranking by 2016 revenue or latest available figure (Supporting Information Table 5). [b] Status mid‐2016. [c] Ranked #1 in acquisition year 2008. [d] Ranked #37 in acquisition year 2008. [e] Ranked among top‐10 in acquisition year 2006.